Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed EGFR wild type, ALK negative, non-squamous cell carcinoma, locally advanced and metastatic disease stage IIIB and IV. Evidence of disease progression after one cytotoxic treatment platinum containing regimen. Immunotherapy pretreatment is allowed~2. Complete recovery from prior chemotherapy side effects to \< Grade 2.~3. At least one unidimensionally measurable lesion meeting RECIST criteria.~4. ECOG PS 0-1.~5. Age ≥ 18 years.~6. Adequate organ function, including:~   * Adequate bone marrow reserve: ANC \> 1.5 x 109/L, platelets ≥ 100 x 109/L.~  * Hepatic: bilirubin ≤1.5 x ULN (upper limit normal), AP, ALT, AST ≤ 1.5 x ULN. AP, ALT, and AST ≤5 x ULN is acceptable if the liver has tumor involvement.~  * Renal: calculated creatinine clearance ≥ 40 ml/min based on the Cockcroft-Gault formula.~7. Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate. Female patients with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment.~8. Signed informed consent.~9. Patient compliance and geographical proximity that allow adequate follow up.~10. Patients who have undergone cranial irradiation for brain metastases more than 4 weeks before inclusion in our protocol, provided that they are clinically fit to undergo second line treatment~Exclusion Criteria:~1. Pregnant or lactating women.~2. Patients with medical risks because of non-malignant disease as well as those with active uncontrolled infection.~3. Documented brain metastases unless the patient has completed local therapy for central nervous system metastases at least 4 weeks before enrollment and has been off corticosteroids for at least two weeks before enrollment. Prophylactic irradiation at least 4 weeks prior to enrollment is accepted.~4. Maintenance treatment with erlotinib or other TKI (Tyrosine Kinase Inhibitor), or docetaxel. Maintenance treatment with pemetrexed is allowed. Previous treatment with an EGFR-TKI or docetaxel within 6 months prior to enrollment.~5. Inability or unwillingness to take dexamethasone.~6. Concomitant treatment with any other experimental drug under investigation.~7. Patients experiencing disease progression within 2 months after the start of platinum based chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel (Type: ACTIVE_COMPARATOR): Docetaxel 75mg/m2 every 21 days until disease progression or toxicity related
- Docetaxel plus erlotinib (Type: ACTIVE_COMPARATOR): Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days, until disease progression, or toxicity related.

Based on this trial design, predict the completion outcome and termination type (if applicable).